Why Retatrutide's Glucagon Receptor Activation Matters
Retatrutide differs from tirzepatide by activating the glucagon receptor, adding metabolic effects beyond GLP-1/GIP modulation.
1) Enhanced weight loss: Clinical data show up to ~24% weight loss vs ~16% with tirzepatide, driven by higher energy expenditure and increased fat oxidation.
2) Liver fat reduction: Over 85% of participants achieved normalized liver fat levels, reflecting improved hepatic fat breakdown and reduced lipogenesis.
3) Cardio-metabolic benefits: Better lipid handling and metabolic efficiency suggest potential cardiovascular advantages beyond appetite suppression.
These mechanisms position retatrutide as a promising option for broader cardiometabolic health and fatty liver improvement.
